—
Swiss credit: Breathe easy. Rating agency S&P confirms “A +” rating after Greensill affair. Company boss Thomas Gottstein does not rule out a spin-off of asset management in the weekend press. Corresponding speculations were already circulating on Friday.
Richemont: I rejected an informal takeover offer from Kering in January, reports the luxury goods blog “Miss Tweed”. Bernstein Research goes to OUTPERFORM (Market Perform) to 116 (90) Fr. Better late than never.
Bachem: Mirabaud Securities shares a buy at BUY up to CHF 544 (500). Increases earnings estimates by an average of 15 percent. The sky is the limit.
Conzzeta: Research Partners go to HOLD (Buy) to 1300 (1400) Fr. Transformation process and future margin improvements largely priced in.
GAM: Gerda Caner is investing 3.12 percent through Uccelini Ltd. Does that mean the mysterious buyer of the last few weeks finally has a name?
Interroll: Credit Suisse is up to CHF 2634 (2450) for UNDERPERFORM. Profit estimates are increased by an average of 6 percent. Share continues to be overvalued.
LafargeHolcim: JP Morgan increases to 60 (57) Fr. with OVERWEIGHT. Welcomes the cost improvements.
Novartis: Bernstein Research starts with MARKET PERFORM up to CHF 88. Broad development pipeline. A certain skepticism remains, however.
Relief Therapeutics: Licensed active ingredient ACER-001 from Acer Therapeutics.
Roche: Receives positive mention in the US investor magazine Barron’s on the subject of Alzheimer’s research. Tecentriq achieves study goals in lung cancer. ZKB is delighted for OVERWEIGHT.
SGS: Faced with allegations of corruption. SocGen remains unimpressed with HOLD up to CHF 3000 (2800). Not so Vontobel. Reduces to HOLD (Buy) to 2900 (2950) Fr.
Swatch Group: Bernstein Research goes to OUTPERFORM (Market Perform) to 35 (260) Fr. Sales markets more resilient than expected.
Swiss Steel: Kepler Cheuvreux is for REDUCE up to 0.15 (0.10) Fr.
Vetropack: Research Partners increase to 65 (60) Fr. Surprisingly cautious statements on this year’s margin development.
To the Rose: Merrill Lynch firm, is for BUY up to 600 Fr. Sees a unique entry opportunity in the course fiasco.
Derivatives: Sales are limited to the knock-out put SSMACV on the SMI as well as the Long Mini-Future MGOAPV Gold.
–
